Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners.
Bill Snider, Partner at BroadOak Capital Partners commented: “We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland is a highly respected and innovative business that has seen significant recent growth. Increasing its reach and leveraging its core assets was an opportunity that we are thrilled to support. Customers of both companies will undoubtedly reap the benefits of the combination.”
The full press release is below.
Rockland Immunochemicals, Inc. announces acquisition of antibodies-online GmbH and investment from BroadOak Capital
LIMERICK, PA, UNITED STATES, February 10, 2022 /EINPresswire.com/ — Rockland Immunochemicals, Inc. (Rockland), a leader in life science tools and services, announced today that it has completed the acquisition of antibodies-online GmbH (antibodies-online). With offices in Europe and the U.S., antibodies-online provides antibodies and other reagents to scientists in more than 65 countries, accelerating and enabling scientific discovery and the development of therapies and diagnostics. antibodies-online makes the complex convenient by guiding each scientist with curated and accurate product selections to unmatched product and validation data on its e-commerce platform. The acquisition combines Rockland’s excellence in the design, development, and manufacture of antibodies and assays with antibodies-online’s trusted e-commerce brand, broad supplier network, and proprietary technology stack. Customers of each company will have access to enhanced capabilities that are supported by broader and deeper data sets, enriching the customer experience and advancing the customer’s go-to-market strategy.
Jim Fendrick, President and CEO of Rockland commented: “The discovery and delivery to market of tomorrow’s biologic, cell, gene, and RNA therapies, diagnostics, and vaccines requires rigor and a keen dedication to the quality of each element of the ecosystem that supports the research, development, approval, and production of our customers’ products. Adding antibodies-online’s talents and capabilities brings both scale and supply chain stability to our offering. Our customers will have access to our depth of antibody and assay expertise across a broader spectrum of disease targets to assure that their products are safe, sustainable, and achieve market access.”
Tim Hiddemann, co-founder and Managing Director of antibodies-online, said: “We are excited about the opportunity to join the Rockland group and provide our customers with in-depth subject matter expertise that will advance meaningful scientific discovery and provide additional assurance in the quality of our customers’ work and products. Our ability to curate vast data sets and present them cogently on our platform is critical as new complex therapies and supporting scientific work are reliant on antibody technology to demonstrate target identification, purity, and potency. Together, with Rockland, we deliver more value to discerning customers who demand quality delivered with consistency.”
Bill Snider, Partner at BroadOak Capital Partners commented: “We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland is a highly respected and innovative business that has seen significant recent growth. Increasing its reach and leveraging its core assets was an opportunity that we are thrilled to support. Customers of both companies will undoubtedly reap the benefits of the combination.”
Stay connected
Partner with BroadOak